Kornimate/medical-research-clean huggingface dataset:
early detection and screening strategy of gatric cancer in sichuan province-a prospective cohort study (wch-gc-siges-01)

Conditions: Neoplasm, Stomach; H. Pylori Infection; Chronic Atrophic Gastritis

Summary: to establish prospective cohort of healthy population and corresponding serum sample bank in sichuan province to provide platform for exploring early diagnosis and screening strategy of gastric cancer by a prospective cohort study.

h. pylori was one of the most important carcinogenic factor for gastric cancer and play a crucial role in inducing gastritis, atrophy and canceration. chronic atrophic gastritis (cag) was a common precancerous disease, people with cag become high-risk population and need regular follow-up. however, study about occurrence risk prediction for gastric cancer when h. pylori infection concurrence with cag was still spare. in especial, there was still no population screening program based on serology. the relative clinical epidemiology for providing evidence for china gastric cancer screening program was very rare. this study aim to evaluate gastric cancer occurrence risk and diagnostic value of people combined with h. pylori infection and cag by serological methods in sichuan province china. we also project to design optimized screening program suitable for people in sichuan province china.

Eligibility criteria:
inclusion criteria: 1. inhabitant in sichuan province in china (length of residence \> 10 years); 2. complete physical examination in our hospital, the outcomes was asymptomatic and cancer free healthy individuals; 3. age between 20 and 70; 4. with normal cognitive and communication ability; 5. without gastroscopy during recruitment, physical examination item including gastroscopy enrolled in prospective cohort study; 6. wiling to accept 1-2 times routine physical examination in our hospital; 7. agree to accept the follow-up of our project group; exclusion criteria: 1. with history of malignant tumor; 2. refuse to donate blood specimen; 3. with serious comorbidity and/or finite life (less than 5 years); 4. request to retreat from this study;

Keywords: gastric carcinoma early diagnosis screening stragety health population cohort
water for reducing pain in negative pressure wound therapy

Conditions: Treatment

Summary: negative pressure wound therapy (npwt) is a technique using vacuum dressing to promote wound healing in complicated wound. however for many patients, the application and removal of the npwt is source of procedural pain. some techniques had been reported to reduce these pain such as administering topical lidocain or normal saline solution before the dressing change. the authors hypothesized that administering cold water into the npwt sponge would decrease pain during dressing changes.


Eligibility criteria:
inclusion criteria: * open wounded patient who is treated by negative pressure wound therapy (npwt) with the age between 18-70 years old. exclusion criteria: * the patient who has decrease sensation at cured wound region * the patient who has glasgow coma scale less than 15 * the patient who cannot provide pain scale data * the patient who has diabetic ulcer or other chronic sores * the patient who denies to participate in research project.

Keywords: cold water negative pressure wound therapy pain
cervical laminoplasty versus laminectomy and fusion: the long-term results comparison

Conditions: Myelopathy Cervical

Summary: the objective of this study is to retrospectively analyze and compare the long-term clinical and radiographic results of multi-level laminoplasty to multi-level laminectomy and fusion for the treatment of patients with cervical myelopathy or myeloradiculopathy.


Eligibility criteria:
inclusion criteria: * patients aged at least 18 years * the patient has the diagnosis of degenerative cervical myelopathy * the myelopathy or myeloradiculopathy requires a posterior cervical decompression of the spinal canal involving two or more contiguous intervertebral levels including and between c3 and c7 * more than five years of follow-up time exclusion criteria: * presence of primary focal anterior compression of the cervical spinal cord * previous surgery of the cervical spine * tumor, infection, or trauma of the cervical spine or cord * patients with ankylosing spondylitis * patients with neurodegenerative diseases, or any neuropathies
impact of metabolic syndrome on rehabilitation outcomes in rotator cuff injury

Conditions: Rotator Cuff Injury (RCI); Metabolic Syndrome (MetS)

Summary: this prospective comparative study aims to investigate the effect of metabolic syndrome (mets) on the outcomes of a standardized rehabilitation program in patients with rotator cuff injuries (rci). patients diagnosed with rci will be divided into two groups based on the presence or absence of mets, determined by ncep-atp iii criteria. both groups will receive the same 4-week physiotherapy protocol including hot pack, tens, ultrasound, and therapeutic exercises. pain intensity, pain threshold, muscle strength, kinesthesia, and shoulder functionality will be evaluated before and after treatment. the study hypothesizes that the presence of mets negatively affects rehabilitation outcomes in patients with rci by altering inflammation and tissue healing processes.

this study aims to investigate the differences in shoulder function and rotator cuff tear outcomes between individuals with and without metabolic syndrome (mets). participants will be divided into two groups: the mets group, which meets at least three of the ncep-atp iii criteria for metabolic syndrome, and the non-mets group, which does not have mets. both groups will undergo an initial assessment, focusing on shoulder function, rotator cuff tear status, and associated factors such as age, gender, and general health conditions. the study will explore how mets may impact the recovery and function of the shoulder in individuals with rotator cuff tears, aiming to provide insights into potential treatment and rehabilitation strategies for this population. data will be collected at a single time point (cross-sectional study) to evaluate baseline conditions and differences between the two groups. statistical analyses will be performed to compare outcomes and explore potential correlations with mets criteria.

Eligibility criteria:
* inclusion criteria for the non-mets group: * aged between 18-65 years * willing to participate in the study * unilateral rotator cuff tear (rmy) * inclusion criteria for the mets group: in addition to the above criteria, meeting at least three of the ncep-atp iii consensus criteria for metabolic syndrome stable metabolic syndrome (e.g., no significant medical changes in the last 3 months) - exclusion criteria for all participants: * inability to cooperate with the tests or presence of mental health issues * presence of cervical radiculopathy symptoms * presence of other orthopedic pathologies in the same shoulder (e.g., fracture, prosthesis, avascular necrosis, advanced shoulder osteoarthritis, frozen shoulder, severe scapular dyskinesia, neurological diseases, etc.) * presence of function-limiting neurological, vascular, or cardiac issues * local steroid injection to the shoulder within the last 3 months * receipt of physiotherapy or rehabilitation within the last 3 months * systemic rheumatic or inflammatory diseases * surgical history due to chronic rotator cuff tear * diagnosis of glenohumeral joint or acromioclavicular joint arthritis * severe scapular dysfunction or significant postural abnormalities
comparison of cervical ultrasound and echoscintigraphy for preoperative localization diagnosis in primary hyperparathyroidism

Conditions: Primary Hyperparathyroidism

Summary: the biological diagnosis of the primary hyperparathyroidism is now facilitated by the reliability of the balance of phosphate and calcium and the dosage of parathyroid hormone (pth). this diagnosis of preoperative localization is important as surgery are now targeted to the responsible lesion. the "gold standard" for this localization is the cervical ultrasound exploring the usual sites of adenomas and a mibi scintigraphy (the parathyroid adenoma significantly concentrating this cell marker). however, the diagnosis of preoperative localization remains a subject of discussion as to the most appropriate tests. indeed, the morphological diagnosis is performed at the ultrasound stage in more than half the cases. it is the new performance of this morphological examination that makes it possible to obtain these results.


Eligibility criteria:
inclusion criteria: * patients with primary hyperparathyroidism with surgery indication * age \> 18yo exclusion criteria: * surgical contraindication * medical treatment by cinacalcet * non sporadic hyperparathyroidism * age \<18yo * protected by the law

Keywords: primary hyperparathyroidism cervical ultrasound echoscintigraphy
transcutaneous auricular neurostimulation after lumbar fusion surgery

Conditions: Pain, Postoperative; Opioid Use; Lumbar Spine Injury

Summary: the purpose of this study, entitled "delivering transcutaneous auricular neurostimulation as an adjunct non-opioid pain management therapy for patients undergoing lumbar fusion surgery", is to demonstrate whether transcutaneous auricular neurostimulation (tan) can non-invasively reduce the perception of pain in patients undergoing lumbar fusion surgery. tan is placed on and around the ear to non-invasively stimulate branches of the vagus and trigeminal nerves and modulate specific brain regions associated with pain.

this study is designed as a randomized, double-blind, sham-controlled, single-center, clinical trial in which 20 patients undergoing lumbar fusion surgery will be randomized 1:1 into one of two treatment groups: 1. group 1 (n=10): active tan + standard care 2. group 2 (n=10): sham tan + standard care stimulation: participants undergoing lumbar fusion surgery will be randomized to receive either active or sham tan treatment according to the following time points: * pre-operative: 30 minutes in the hour prior to surgery * intra-operative: 30 minutes before the end of surgery * post-operative: 30 minutes at 3 and 6 hours after surgery * inpatient: four 30-minute sessions on day 2 blood draws participants will have blood samples collected at the following time points: * day 1 (day of surgery) * day 2 (day 1 post-surgical) follow up visits participants will have study follow up visits on days 7 and day 14. these visits can either be conducted either via a secure telehealth video visit, or in person visit.

Eligibility criteria:
inclusion criteria: 1. medically cleared to undergo a lumbar fusion surgery 2. 18-85 years of age 3. english proficiency 4. participants must be able to provide informed consent and function at an intellectual level sufficient for study requirements exclusion criteria: 1. current evidence of an uncontrolled and/or clinically significant medical condition 2. history of bleeding disorders or coagulopathy 3. history of seizures or epilepsy 4. history of neurological diseases or traumatic brain injury 5. use of illegal recreational drugs 6. presence of devices, e.g. pacemakers, cochlear prosthesis, neuro-stimulators 7. use of acupuncture within 4 weeks of surgery 8. grossly abnormal external ear anatomy or active ear infection 9. women of childbearing potential, not using effective contraception per investigator judgment or not willing to comply with contraception for the duration of the study 10. females who are pregnant or lactating 11. any other significant disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial

Keywords: lumbar fusion transcutaneous auricular neurostimulation (tan)
clinical evaluation of carestream vue pacs v12.2 mr perfusion and diffusion

Conditions: Ischemia

Summary: the objective of this study is to compare the diagnostic value of mr dsc-perfusion (perfusion module), mr dwi (diffusion module) and mr dti (diffusion module) in carestream vue pacs ("investigational device") to the olea sphere pacs with perfusion and dwi modules ("predicate device"). therefore, there will be several separate objectives depending on the type of acquisition:

carestream health, inc. will investigate the imaging performance of the carestream vue pacs v12.2 magnetic resonance (mr) perfusion and diffusion weighted imaging ("investigational device") performance. evaluation of mr dynamic susceptibility contrast-enhanced perfusion weighted imaging (dsc-perfusion), mr diffusion weighted imaging (dwi) and mr diffusion tensor imaging (dti) was compared to the predicate device, the olea sphere pacs with perfusion and dwi modules. mr dsc-perfusion of the brain is a method for evaluating blood flow in the brain and producing optimized parametric maps that help visualize this blood flow. mr dwi is a method to evaluate the motion of water molecules within bodily tissues. mr dti is an extension of dwi that allows extraction of the diffusion tensor. the purpose of this study is to demonstrate equivalent clinical quality between the investigational and predicate devices using a radiologist evaluation of key metrics which are applicable to mr dsc-perfusion, mr dwi, and mr dti images.

Eligibility criteria:
inclusion criteria: * retrospective patient mr dsc-perfusion cases with subject/patient 18 years of age or older. * retrospective patient mr dwi with subject/patient 18 years of age or older. * retrospective patient mr dti cases with subject/patient 18 years of age or older. * informed consent is not required if waiver of consent is approved by the hospital irb/ethics committee exclusion criteria: * low quality images, or images that are not clinically acceptable for clinical diagnostic reading as determined by the principal investigator * subject less than 18 years of age
study on efficacy and safety of givinostat versus hydroxyurea in patients with polycythemia vera

Conditions: Polycythemia Vera

Summary: the goal of this clinical trial is to compare the efficacy and safety of givinostat to hydroxyurea in jak2v617f-positive high risk polycythemia vera patients.


Eligibility criteria:
inclusion criteria: * patients must have been diagnosed with pv according to the 2016 who criteria within 3 years before randomization * patients must have jak2v617f-positive disease * patients with pv must meet the definition of hr for thrombosis (i.e., hr) at screening as follows: * age ≥ 60 years, and/or * prior thrombosis. * patients must be in need of treatment at screening, defined by the presence of at least one of the following: * hct ≥ 45% or hct \< 45% with at least 1 phlebotomy performed in the 3 months before screening, or * wbc count \> 10 × 109/l, or * plt count \> 400 × 109/l. * patients must have normalized hct (i.e., hct \< 45%) at randomization exclusion criteria: * patients pre-treated with hu with a documented history of resistance or intolerance to hu defined by the original eln criteria * patients with a qtcf value of \> 450 msec for males and \> 460 msec for females at the screening visit (as the mean of 3 consecutive readings 5 minutes apart in the event a first ecg demonstrates a prolonged qtcf interval); congenital or acquired history of qtc prolongation or ventricular arrhythmias, at the screening visit * splanchnic thrombosis and/or thrombosis of the cerebral venous sinuses and/or splenectomy in the medical history * patients with clinically significant cardiovascular disease * patients with myocardial infarction, stroke or unstable angina within the 6 months prior to screening. * patients with inadequate liver or renal function at screening * uncontrolled hypertriglyceridemia at screening, i.e., triglycerides ˃ 1.5 × uln * previous treatment with a jak2 or hdac inhibitor or 32-phosphorus (radioactive isotope) therapy. * patients being treated concurrently with any investigational agent or prior participation in an interventional clinical study within the 30 days prior to screening or within 5 half-lives of the investigational product, whichever is longer. * pregnant or nursing women
low level laser therapy versus pharmacotherapy in in improving masticatory muscle pain

Conditions: TMD

Summary: tempromandibuar disorders are a group of heterogenous pathologies affecting temporomandibular joint,muscles or both.in more than 90%of cases muscles are the origin of pain.tmds cause pain,movement disability and deficit in quality of life.in more than 90%of cases pain is the major complaint.we run this investigation to find the analgesic effct of low level laser therapy versus pharmacotherapy with naproxen in improving pain.


Eligibility criteria:
inclusion criteria: * patients with tmd affecting masticatory muscles exclusion criteria: * systemic disease * gi problem * pregnancy * epidermal cancer

Keywords: temporomandibular disorder myofascial pain syndrome
biomarkers in predicting response to cetuximab in patients with advanced colorectal cancer

Conditions: Colorectal Cancer

Summary: rationale: studying samples of tissue in the laboratory from patients who received cetuximab may help doctors understand and predict how well patients will respond to treatment. purpose: this research study is studying biomarkers in predicting response to cetuximab in patients with advanced colorectal cancer.

objectives: primary * to determine, among patients with advanced crc, whether the effect of treatment (cetuximab vs bevacizumab) on progression-free survival (pfs) depends on tumor braf v600e mutational status. secondary * to study the relationships between tumor braf v600e mutational status, os, and tumor response. outline: this is a multicenter study. previously collected formalin-fixed and paraffin-embedded baseline tumor samples are analyzed for braf v600e mutation. mutation status is correlated with clinical response and outcome data from patients enrolled on calgb-c80405.

Eligibility criteria:
disease characteristics: * participation in calgb-c80405 * have kras wt or kras mut tumor * randomized to treatment with either bevacizumab or cetuximab alone * patients randomized to the combination therapy are not eligible * available specimens at the pco for braf mutation detection * patient consent for use of samples

Keywords: recurrent colon cancer stage iiia colon cancer stage iiib colon cancer stage iiic colon cancer stage iva colon cancer stage ivb colon cancer recurrent rectal cancer stage iii rectal cancer stage iv rectal cancer
a study of pegasys (peginterferon alfa-2a (40kd)) plus ribavirin in hemophiliac patients with chronic hepatitis c.

Conditions: Hepatitis C, Chronic

Summary: this study will evaluate the efficacy and safety of pegasys plus ribavirin in male patients with hemophilia a and chronic hepatitis c. all patients will receive pegasys 180 micrograms s.c. weekly plus ribavirin 1000-1200mg p.o. daily (depending on body weight) for 48 weeks. following treatment there will be a 24 week period of treatment-free follow-up. the anticipated time on study treatment is 3-12 months, and the target sample size is \<100 individuals.


Eligibility criteria:
inclusion criteria: * male patients, \>=18 years of age; * hemophilia a; * chronic hepatitis c; * compensated liver disease. exclusion criteria: * therapy with any systemic anti-viral, anti-neoplastic or immunomodulatory treatment \<=6 months before start of study drug; * hepatitis a, hepatitis b or hiv infection; * chronic liver disease other than chronic hepatitis c.
genosvid diagnostic test for early detection of covid-19

Conditions: COVID-19

Summary: electronic-nose had been used to diagnose other infectious lung diseases, such as tuberculosis. universitas gadjah mada has developed an electronic-nose device which is easy-to-use, portable, and can be manufactured at a low price. here the investigators test the electronic-nose to diagnose covid-19 in indonesia.

the validation of device is conducted to 43 confirmed covid-19 patients and 40 confirmed covid-19 negative patients from bhayangkara hospital, rslkc bambalipuro in yogyakarta special region, indonesia. afterwards, patients with symptoms suggesting covid-19 will be recruited using multicentre consecutive sampling. the minimum number of participants required is 1460 subjects. the study use a triple-blind design where the research subjects, breath sample takers, and sample examiners did not know the results of each sampling that had been done. the final data processor was also blinded to the results of nose and throat swabs. the breath sampling data is saved in graphic form which interpretation will be carried out later by the data processor at the final stage. this study population involve children and adults who come to the covid-19 outpatient clinic in each participating hospital with a diagnosis of suspected covid-19 infection. all patients remain in the setting under medical service in accordance with the standard operating procedure (sop) and clinical practice guidelines (cpg) protocols for handling patients with suspected covid-19. the patients underwent nasal and oropharyngeal swabs according to the covid-19 outpatient cpg. the participants will be asked about symptoms that they have, such as fever, fatigue, dry cough, stuffy/ runny nose, sore throat, myalgia, shortness of breath, and diarrhea. afterwards, they will be asked to breathe normally using a mask for 2 times, then inhale and exhale in a forced expiratory volume to an air collecting bag that later is connected to the e-nose machine via a hepa-filter. the performance of breath test will be compared with the performance of symptoms with the reference of rt-pcr results. in addition, participants' demographic and clinical data will be collected.

Eligibility criteria:
inclusion criteria: * patients diagnosed with covid-19, non covid-19, and suspected covid-19 infection, based on the results of anamnesis, physical examination, laboratory, x-rays and rapid tests. * able to produce samples for rt-pcr examination. * agree to participate (sign informed consent). for children, informed consent are obtained from the parents. for adolescent patients, accent consent is asked. * patients who do not need oxygen therapy supplementation in the form of mask-type or ventilator. patients who use oxygen supplementation with nasal cannula are still included as study participants. exclusion criteria: * unable to breath deeply due to difficulty breathing due to complications of covid-19 or other diseases * the quality of the breath do not meet the standard interpretation of the instrument sensor curve (breath sampel is declared invalid).

Keywords: covid-19 diagnosis electronic nose
an bioequivalence study of xanax extended release tablets from two different manufacturing sites

Conditions: Healthy Subjects

Summary: study to evaluate if xanax sustained release tablets manufactured at two different sites provide similar drug levels in the blood.


Eligibility criteria:
inclusion criteria: * healthy male and/or female subjects between the ages of 20 and 55 years, inclusive. * an informed consent document signed and dated by the subject. exclusion criteria: * evidence or history of clinically significant abnormality. * a positive urine drug screen. * subjects who are hypersensitive to alprazolam or related compounds.

Keywords: alprazolam xanax bioequivalence panic disorder with or without agoraphobia.